Valuation: Medivir AB

Market Cap 1.05B 107M 92.88M 87.7M 79.64M 149M 10.22B 150M 405M 5.2B 400M 391M 16.72B P/E 2026 *
-11.1x
P/E 2027 * -7.78x
Enterprise Value 954M 96.78M 84.39M 79.68M 72.36M 136M 9.29B 136M 368M 4.72B 364M 355M 15.19B EV / Sales 2026 *
207x
EV / Sales 2027 * 6.1x
Free-Float
63.91%
Yield 2026 *
-
Yield 2027 * -
1 day-3.19%
1 week-6.59%
Current month-13.00%
1 month+2.66%
3 months+4.81%
6 months-24.44%
Current year+315.65%
1 week 1.7
Extreme 1.696
1.82
1 month 1.7
Extreme 1.696
2.16
Current year 0.39
Extreme 0.392
2.88
1 year 0.34
Extreme 0.34
2.88
3 years 0.34
Extreme 0.34
8.25
5 years 0.34
Extreme 0.34
11.84
10 years 0.34
Extreme 0.34
102
Manager TitleAgeSince
Chief Executive Officer 55 24/01/2022
Director of Finance/CFO - 23/03/2026
Chief Tech/Sci/R&D Officer 60 20/02/2023
Director TitleAgeSince
Chairman 76 05/05/2021
Director/Board Member 70 03/05/2018
Director/Board Member 47 05/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
27/07/26
Hallberg Management AB
BuyCompany 6,097,560 0.9868%
18/06/26 Buy

Chief Financial Officer

18,000 0.0033%
05/12/25 Buy 90,000 0.0802%
Change 5-day change 1-year change 3-year change Capi.($)
-3.19%-6.59%-1.28%-77.92% 107M
-0.31%+5.79%+48.93%+97.53% 70.88B
+0.39%+2.06%+40.91%+78.49% 62.49B
-3.21%-7.27%-17.73%+351.98% 26.21B
+0.50%+7.13%+29.43%+15.48% 26.34B
-2.64%-0.69%-0.26%-11.90% 24.13B
+0.71%+8.03%+27.22%-13.18% 20.72B
-1.26%-7.81%+169.33%+302.38% 15.36B
-0.22%+3.99%+44.28%+173.35% 14.46B
+0.73%+1.71%-7.18%+886.19% 14.25B
Average -0.85%+0.82%+33.37%+180.24% 27.49B
Weighted average by Cap. -0.47%+1.44%+36.49%+147.89%

Financials

2026 *2027 *
Net sales 4.6M 466K 407K 384K 349K 653K 44.75M 656K 1.78M 22.75M 1.75M 1.71M 73.21M 148M 15.06M 13.13M 12.4M 11.26M 21.09M 1.44B 21.18M 57.31M 735M 56.56M 55.3M 2.36B
Net income -72.78M -7.38M -6.43M -6.08M -5.52M -10.34M -708M -10.38M -28.08M -360M -27.72M -27.1M -1.16B 33.53M 3.4M 2.96M 2.8M 2.54M 4.76M 326M 4.78M 12.94M 166M 12.77M 12.49M 534M
Net Debt -96M -9.73M -8.49M -8.01M -7.28M -13.64M -934M -13.69M -37.05M -475M -36.56M -35.75M -1.53B -145M -14.7M -12.82M -12.1M -10.99M -20.59M -1.41B -20.68M -55.95M -717M -55.23M -54M -2.31B
Logo Medivir AB
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Employees
6
Date Price Change Volume
18/09/26 SEK 1.700 -3.19% 1,194,965
17/09/26 SEK 1.756 +2.09% 1,775,289
16/09/26 SEK 1.720 -1.15% 899,002
15/09/26 SEK 1.740 -1.81% 1,163,695
14/09/26 SEK 1.772 -2.64% 853,659
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.700SEK
Average target price
5.768SEK
Spread / Average Target
+239.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MVIR B Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!